financetom
Business
financetom
/
Business
/
GCM Grosvenor Files $350 Million Shelf Registration for Mixed Securities
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
GCM Grosvenor Files $350 Million Shelf Registration for Mixed Securities
Jun 27, 2025 2:00 PM

04:36 PM EDT, 06/27/2025 (MT Newswires) -- GCM Grosvenor ( GCMG ) filed a registration statement with the US Securities and Exchange Commission on Friday to offer up to $350 million in securities.

The registration statement covers class A common and preferred stock, debt securities, depositary shares, warrants, purchase contracts and units.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Niu Technologies Q3 Sales Volume Rises
Niu Technologies Q3 Sales Volume Rises
Oct 6, 2025
04:36 AM EDT, 10/06/2025 (MT Newswires) -- Niu Technologies ( NIU ) said Monday its Q3 sales volume was 465,873 units, up from 312,405 a year earlier Sales in China rose to 451,455 units from 259,094, while international sales dropped to 14,418 from 53,311, according to the producer of electric-powered motorcycles, mopeds, bicycles and scooters The company's shares were up...
Oculis to Advance Privosegtor to Registrational Trials for Neuro-Ophthalmology Indications
Oculis to Advance Privosegtor to Registrational Trials for Neuro-Ophthalmology Indications
Oct 6, 2025
04:54 AM EDT, 10/06/2025 (MT Newswires) -- Oculis Holding ( OCS ) said Monday it is advancing its Privosegtor product candidate to a registrational program for neuro-ophthalmology indications following a positive meeting with the US Food and Drug Administration. The company plans to start the program this year, with three trials to support the registration process. The first trial is...
Arvinas Says Potential Parkinson's Disease Treatment Well Tolerated in Early Trials; Shares Gain Pre-Bell
Arvinas Says Potential Parkinson's Disease Treatment Well Tolerated in Early Trials; Shares Gain Pre-Bell
Oct 6, 2025
04:30 AM EDT, 10/06/2025 (MT Newswires) -- Arvinas ( ARVN ) said Sunday its ARV-102 experimental drug was well tolerated in both healthy volunteers and patients with Parkinson's disease in two phase 1 trials. The company said ARV-102 was safe at single and multiple doses, and significantly reduced levels of LRRK2 protein, adding that LRRK2 mutations are a frequent familial...
Danaos Plans $500 Million Private Debt Offering; Shares Up Pre-Bell
Danaos Plans $500 Million Private Debt Offering; Shares Up Pre-Bell
Oct 6, 2025
05:17 AM EDT, 10/06/2025 (MT Newswires) -- Danaos ( DAC ) said Monday it plans a private offering of up to $500 million of senior notes due 2032, subject to market conditions and other factors. The company intends to use the net proceeds to fully redeem the $262.8 million outstanding principal amount of its 8.5% senior notes due 2028 on...
Copyright 2023-2026 - www.financetom.com All Rights Reserved